In summary, the present study demonstrates that MeCP2, a target of miR-638, functions as an oncogene that facilitates GC cell proliferation and induces cell-cycle progression through activation of the MEK1/2–ERK1/2 signaling pathway by upregulating GIT1. Here, MAP2K1 is linked to gastric cancer.